Methotrexate injection: An old drug with a newly developing landscape

Author:

Tan Ning1ORCID,Hsu Chi‐Jen2ORCID,Mo Han‐You3ORCID,Yang Xiuyan145,Wei James Cheng‐Chung6789ORCID

Affiliation:

1. Department of Traditional Chinese Medicine and Rheumatology Huazhong University of Science and Technology Union Shenzhen Hospital Shenzhen China

2. Department of Orthopedics The Fifth Affiliated Hospital of Sun Yat‐sen University Zhuhai China

3. Department of Rheumatology and Immunology The First Affiliated Hospital of Guangxi Medical University Nanning China

4. Department of Rheumatology and Immunology Guangdong Clifford Hospital Guangzhou China

5. Department of Rheumatology and Immunology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou China

6. Department of Allergy, Immunology & Rheumatology Chung Shan Medical University Hospital Taichung Taiwan

7. Department of Nursing Chung Shan Medical University Taichung Taiwan

8. Institute of Medicine Chung Shan Medical University Taichung Taiwan

9. Graduate Institute of Integrated Medicine China Medical University Taichung Taiwan

Publisher

Wiley

Subject

Rheumatology

Reference28 articles.

1. Methotrexate in rheumatoid arthritis: a quarter century of development;Weinblatt ME;Trans Am Clin Climatol Assoc,2013

2. Attaching importance to the traditional disease modifying antirheumtic drugs;Yang XY;Chin Med J (Engl),2008

3. A new concept of the classic antirheumatic drug methotrexate;Qiu X, Yang XY;Chin J Intern Med,2010

4. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial

5. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3